Physician profile
Lingling Wu
NPI 1194210310
$1,676.66
in general payments reported to CMS, 2019-2025
16 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $321 · 2023: $688 · 2024: $417 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $383.14 | 2022-2024 | Xarelto |
| Inari Medical, INC. | $262.77 | 2022-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Merck Sharp & Dohme LLC | $202.75 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.34 | 2022-2025 | Xifaxan |
| Alexion Pharmaceuticals, INC. | $152.03 | 2022-2025 | Ultomiris |
| Amgen INC. | $79.41 | 2022-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $79.07 | 2022-2023 | Camzyos |
| Melinta Therapeutics, LLC | $53.33 | 2024 | Orbactiv, Kimyrsa, Rezzayo |
| Stryker Corporation | $53.08 | 2025 | Flowtriever, Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abbvie INC. | $52.64 | 2022-2023 | Teflaro |
| Scpharmaceuticals INC. | $33.27 | 2024 | |
| Boston Scientific Corporation | $32.76 | 2023 | Watchman Access System |
| Bioxcel Therapeutics, INC. | $32.67 | 2023 | Igalmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.90 | 2023 | Jardiance |
| Recor Medical INC | $25.79 | 2024 | Paradise Renal Denervation System |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.71 | 2025 | Brilinta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lingling Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.